A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours-Reference-Cited by-同舟云学术

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

Published:2007-11-20 Issue:1 Volume:98 Page:80-85
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Eskens F A L M,Mom C H,Planting A S T,Gietema J A,Amelsberg A,Huisman H,van Doorn L,Burger H,Stopfer P,Verweij J,de Vries E G E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6604108.pdf

Reference20 articles.

1. Agus D, Terlizzi E, Stopfer P, Amelsberg A, Gordon M (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24: 49s (suppl, abstract 2074)

2. Baselga J, Rischin D, Ranson M, Cavert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Averbuch S, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292–4302

3. Burris H, Hurwitz H, Dees E, Dowlati A, Blackwell K, O'Neil B, Marcom P, Ellis M, Overmoyer B, Jones S, Harris J, Smith D, Koch K, Stead A, Mangum S, Spector N (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305–5313

4. Carter E, Wodicka L, Shah N, Velasco A, Fabian M, Treiber D, Milanov Z, Atteridge C, Biggs W, Edeen P, Floyd M, Ford J, Grotzfeld R, Herrgard S, Insko D, Mehta S, Patel H, Pao W, Sawyers C, Varmus H, Zarrinkar P, Lockhart D (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011–11016

5. Dittrich Ch, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38: 1072–1080

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells;Cancer Letters;2023-12

2. Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy;Cancers;2023-11-21

3. Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities;Journal of Medicinal Chemistry;2023-02-22

4. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations;Medicinal Chemistry Research;2022-09-01

5. Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study;Clinical Pharmacology in Drug Development;2022-07-06